Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board

Published: Thursday, December 20, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.

Gentronix Ltd., Manchester UK, has been awarded a grant of £147,552 by the Medical Research Council (MRC) and the Technology Strategy Board under the joint £180 million Biomedical Catalyst programme.

The project funded by the award will look at the feasibility of developing a screening assay for compounds that may cause cancer as a result of epigenetic mechanisms.

Before being approved for use, chemicals such as pharmaceuticals, agrochemicals and consumer products have to be tested for genetic toxicity i.e. their potential to change the DNA sequence or the number of chromosomes in a cell.

Exposure to genotoxic chemicals can lead to the development of cancers. They can be identified by routine screening tests used by laboratories such as Gentronix.

There are also non-genotoxic carcinogens that alter patterns of gene expression without changing the number or sequence of chromosomes.

There are currently no widely used screening tests available for these and they might only be identified in later animal exposure studies, which are time consuming, costly and come quite late in product development - an expensive time to fail.

Epigenetics is a relatively new field, concerned with the regulation of genes by chromosome modifications which don’t change the DNA sequence or chromosome numbers.

Epigenetic changes can also lead to the development of cancers and it is this aspect of early toxicology screening that the team at Gentronix Ltd., led by Chief Scientist, Prof. Richard Walmsley will be looking to address under the award.

Gentronix CEO, John Nicholson said “Gentronix has an excellent track record of innovation, and though as a growing company we have to balance innovative research with customer priorities, the award of this grant gives us the opportunity to carry out important fundamental research; the results of which will allow us to make informed decisions about the commercial potential of an epigenetics-based assay as well as making a contribution to the science of genetics”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Fighting Cancer Through Protein Pathways
Researchers have found a new drug target within a protein production pathway critical to regulating growth and proliferation of cells.
Mutations in DNA-Repair Genes Found in Advanced Prostate Cancers
New findings indicate that nearly 12% of male advanced prostate cancer sufferers have inherited mutation in DNA-repair genes.
Molecule May Affect Gaucher, Parkinson's Disease
Research has identified a molecule that restores activity of a dysfunctional enzyme linked to Gaucher and Parkinson's disease.
Targeting BRAF Mutations in Thyroid Cancer
Treating metastatic thyroid cancer patients harboring a BRAF mutation with vemurafenib showed anti-tumor activity in a third of patients.
Plant Compounds Fight Together Against Colon Cancer
Research shows treating colon cancer cells with curcumin, then silymarin is more effective than treatment with each individually.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!